Clinical Trial

Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the dose-related safety and tolerability of IPS101A, an adeno-associated virus (AAV) gene therapy, in patients with Parkinson's disease who exhibit severe functional impairment corresponding to Hoehn \& Yahr stages 4-5 and whose symptoms are not adequately controlled despite all available monotherapy and combination therapy options. In addition, the study aims to assess the maximum tolerated dose (MTD) of IPS101A, as well as its preliminary efficacy and pharmacokinetic (PK) characteristics.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2026-01-19; most recent amendment 2026-04-19.
Status change: Not Yet Recruiting → Recruiting 2026-03-23
Trial Details
NCT Number NCT07371338
Lead Sponsor Innopeutics Corporation
Conditions Parkinson Disease, Parkinson's Disease
Enrollment 6 participants
Start Date 2026-05-30
Primary Completion 2027-10-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-21